What precautions should be taken for hepatitis B?

Individuals diagnosed with chronic hepatitis B virus (HBV) infection require lifelong monitoring and proactive management to prevent disease progression, liver complications, and transmission. Key considerations include regular surveillance of liver function tests (ALT, AST), HBV DNA viral load, hepatitis B surface antigen (HBsAg), hepatitis B e-antigen (HBeAg) and anti-HBe status, and quantitative hepatitis B surface antibody (anti-HBs) when relevant. Imaging—typically abdominal ultrasound—is recommended every 6–12 months to screen for hepatocellular carcinoma (HCC), especially in high-risk groups such as those with cirrhosis, family history of HCC, or persistent viral replication.

Antiviral therapy should be initiated based on current international guidelines (e.g., AASLD, EASL, or APASL), considering factors including ALT elevation, high HBV DNA levels (>2,000 IU/mL), evidence of liver inflammation or fibrosis (assessed via non-invasive tests like FibroScan® or liver biopsy), and presence of cirrhosis. First-line agents include entecavir, tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF)—all potent nucleos(t)ide analogues with high barriers to resistance and favorable safety profiles.

Patients must avoid alcohol entirely, as it synergistically accelerates liver injury and increases risk of cirrhosis and HCC. Hepatotoxic medications—including certain herbal supplements (e.g., kava, comfrey), over-the-counter analgesics like acetaminophen in excessive doses, and some prescription drugs—should be used only under physician guidance. Vaccination against hepatitis A and influenza is strongly recommended; pneumococcal vaccination may also be indicated depending on age and comorbidities.

Preventing transmission is essential: sexual partners and household contacts should be tested for HBV and vaccinated if non-immune. Use of condoms reduces sexual transmission risk. Avoid sharing personal items that may carry blood (e.g., razors, toothbrushes, nail clippers). Pregnant individuals with HBV require antenatal screening; those with high viral loads (>200,000 IU/mL) should receive antiviral prophylaxis (typically TDF) from the third trimester to reduce perinatal transmission, and newborns must receive hepatitis B immunoglobulin (HBIG) and the first dose of hepatitis B vaccine within 12 hours of birth.

Psychosocial support is integral—chronic HBV can cause anxiety, stigma, or depression. Patients benefit from counseling, peer support networks, and clear communication about prognosis: with appropriate care, most maintain stable liver health and normal life expectancy. Routine follow-up with a hepatologist or experienced gastroenterologist ensures timely intervention and personalized long-term management.